EORTC 20981

Titel

Chimeric anti-CD20 monoclonal antibody (Mabthera®) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin´s lymphoma.
Akronym

EORTC 20981
Typ av studie Randomiserad, öppen fas-III multicenterstudie
Sponsor

EORTC (European Organization for Research and Treatment of Cancer)
Inklusionskriterier

Ålder >18 år
Stadium III-IV
CD-20 positivt. follikulärt NHL,
Patienter, som har fått återfall efter maximum 2 antracyklin-innehållande kemoterapiregimer, med minst 3 månaders remission på given behandling
WHO-performancestatus 0, 1 eller 2
Studiedesign Rand

CHOP

CHOP + Mabthera
Endpoint(s)

1 Response rate and quality (partial, complete remission, molecular complete remission)
2 Event-free survival
3 Survival
Rekryteringsperiod

1999-11-25 – 2004-04-23
Antal inkluderade patienter 474
Publikationer Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, and Anton Hagenbeek:Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
   
pil Tillbaka till Kliniska prövningar
Uppdaterad: 2008 01 03